Presentation

Biovica develops and commercializes blood-based biomarker assays for evaluating the effect of cancer treatments. DiviTum® measures thymidine kinase activity (TKA), which indicates the cell proliferation rate and clinical studies have shown that it can quickly reveal whether treatment is effective. DiviTum® has the potential to reduce cost and to improve cancer care by monitoring treatment and provide information for better treatment decisions. Research and development, production facilities and the head office are in Uppsala, Sweden. The current customers comprise of pharmaceutical companies and CROs (Contract Research Organizations). Biovica’s strategy is to establish DiviTum® in the much larger clinical oncology market, starting within breast cancer settings.

Recent highlights In the end of July, Biovica received US approval from the FDA for DiviTum, the first FDA approved biomarker for treatment monitoring in hormone receptor positive, metastatic postmenopausal female breast cancer patients.

Outlook The company has already set up a US organization and is now able to launch the product before end of this year. DiviTum® will then be planned for market launches in Europe's five largest markets as well as the Nordic region. More long term Biovica aims to establish DiviTum® in additional markets and for the treatment of more types of cancer and new targeted therapies.